Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review
The prevalence of obesity and diabetes is an increasing global problem, especially in
developed countries, and is referred to as the twin epidemics. As such, advanced treatment …
developed countries, and is referred to as the twin epidemics. As such, advanced treatment …
[HTML][HTML] LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept
T Coskun, S Urva, WC Roell, H Qu, C Loghin… - Cell metabolism, 2022 - cell.com
With an increasing prevalence of obesity, there is a need for new therapies to improve body
weight management and metabolic health. Multireceptor agonists in development may …
weight management and metabolic health. Multireceptor agonists in development may …
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled …
Background Treating hyperglycaemia and obesity in individuals with type 2 diabetes using
multi-receptor agonists can improve short-term and long-term outcomes. LY3437943 is a …
multi-receptor agonists can improve short-term and long-term outcomes. LY3437943 is a …
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
L Gao, BW Lee, M Chawla, J Kim, L Huo, L Du… - Nature Medicine, 2023 - nature.com
Tirzepatide is a once-weekly GIP/GLP-1 receptor agonist. In this phase 3, randomized, open-
label trial, insulin-naive adults (≥ 18 years of age) with type 2 diabetes (T2D) uncontrolled …
label trial, insulin-naive adults (≥ 18 years of age) with type 2 diabetes (T2D) uncontrolled …
[HTML][HTML] Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular …
Background Tirzepatide, a once weekly GIP/GLP-1 receptor agonist, reduces blood glucose
and body weight in people with type 2 diabetes. The cardiovascular (CV) safety and efficacy …
and body weight in people with type 2 diabetes. The cardiovascular (CV) safety and efficacy …
The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets
The incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide
1 (GLP-1) mediate insulin responses that are proportionate to nutrient intake to facilitate …
1 (GLP-1) mediate insulin responses that are proportionate to nutrient intake to facilitate …
Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective
C De Block, C Bailey, C Wysham… - Diabetes, Obesity …, 2023 - Wiley Online Library
Tirzepatide is a novel glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide
1 (GLP‐1) receptor agonist approved in the United States as an adjunct to diet and exercise …
1 (GLP‐1) receptor agonist approved in the United States as an adjunct to diet and exercise …
Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice
A Liskiewicz, A Khalil, D Liskiewicz, A Novikoff… - Nature …, 2023 - nature.com
The development of single-molecule co-agonists for the glucagon-like peptide-1 (GLP-1)
receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) …
receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) …
Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis
B Tan, XH Pan, HSJ Chew, RSJ Goh, C Lin… - International Journal of …, 2023 - nature.com
Background Recent studies suggest that tirzepatide, a dual glucose-dependent
insulinotropic-peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA), has …
insulinotropic-peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA), has …